Abstract: It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicified virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as a T cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant.

Abstract: Innovations in the construction and use of variable-input-length tweakable ciphers (“VILTCs”). In some cases, a VILTC uses an initialization vector that is protected from exposure outside an encryption/decryption system in order to provide enhanced security with efficient performance. For example, a system for encryption and/or decryption includes two fixed-input-length tweakable block ciphers (“FIL TBCs”) and a VILTC. The first FIL TBC is adapted to produce a fixed-length initialization vector. The VILTC is adapted to produce a variable-length output string using the fixed-length initialization vector as a tweak. The second FIL TBC is adapted to produce a fixed-length output string. In this way, the first FIL TBC and the second FIL TBC protect the fixed-length initialization vector from exposure outside the system. In other cases, a VILTC is used for a reliable and efficient implementation of authenticated encryption/decryption with associated data.

Abstract: Embodiments of the present disclosure may be configured to permit development and validation of a device driver or a device application program by using improved virtual devices. Such improved virtual devices may facilitate driver development without use of physical devices or hardware prototypes. In various embodiments, advanced validation of a device-driver combination may be permitted that would be difficult to achieve even with a physical device. Certain embodiments also may detect inconsistencies between virtual and physical devices, which may be used to improve drivers and device application programs and increase compatibility of such drivers and device application programs with physical devices.

Abstract: A distributed wireless monitoring system with a cloud server and low-power remote sensors includes data encoding/compression at sensors to reduce power use from transmission and storage, event activated operation/data logging triggered by configurable thresholds, remote configuration via the cloud server of event triggering thresholds and correlation templates, distributed processing capabilities, and sensor clock synchronization from a network time service.

Abstract: A method is provided for determining specifications that meet electronic system or integrated circuit product requirements at all stages of the product lifecycle. Early in the product lifecycle design features must be specified. Later in the lifecycle datasheet specifications must be determined and published to customers, and test specifications in manufacturing must be determined. The method includes acquiring data from a test vehicle, fitting the data to a copula-based statistical model using an appropriately programmed computer, and using the statistical model to compute producer- and customer-oriented figures of merit of a product, different from the test vehicle, using the appropriately programmed computer. Different size, fault tolerance schemes, test coverage, end-use (datasheet), and test condition specifications of the product may be modeled. The statistical model is a copula-based and so can take into account dependency among attributes of the product.

Abstract: The present teachings provide compounds of Formulae I and II: and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1?, R2, R2?, R3, R3?, and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.

Abstract: Probes for selectively detecting compounds comprising a thiol group and an amino group (“thiols”) are disclosed. Exemplary thiols include cysteine, homocysteine, and glutathione. Embodiments of the disclosed probes produce a detectable change in absorbance spectrum and/or emission spectrum when reacted with one or more thiols in solution. Methods and kits for performing the detection also are disclosed. The probes have a general formula where each bond depicted as “” is a single or double bond; R1, R3-R6 and R8 independently are hydrogen, hydroxyl, thiol, lower alkyl, carboxyalkyl, amino, alkoxy, or halogen; R2 is an ?,?-unsaturated aliphatic ester; R7 is oxygen, sulfur, hydrogen, hydroxyl, thiol, lower alkyl, carboxyalkyl, amino, alkoxy, or halogen, or R7 and R8 together form a cycloalkyl or aryl ring; X1 is CH2, S, NH, O, Se, Si(CH3)2, Ge(CH3)2, Sn(CH3)2, or C(CH3)2; and X2 is CH, CH2, N, NH, or CR9 where R9 is aryl.

Abstract: Embodiments of compounds for selectively detecting a thiol are disclosed. In some embodiments, the compounds are bridged viologens, and the compounds are capable of reacting with homocysteine and/or glutathione in a buffered solution to produce a change in the solution's absorbance spectrum and/or emission spectrum. Also disclosed are embodiments of methods and kits for detecting homocysteine and/or glutathione with the disclosed bridged viologens.

Abstract: Embodiments of compounds for selectively detecting an analyte are disclosed, along with methods and kits for detecting analytes with the compounds. The compounds are bridged viologen conjugates including at least one fluorophore according to the general structure At least one of R1/R2, R2/R3, R3/R4, R5/R6, R6/R7, and/or R7/R8 together form a substituted or unsubstituted cycloalkyl or aryl.

Abstract: Embodiments of near-infrared (NIR) dyes are disclosed, along with methods and kits for detecting analytes with the NIR dyes. The NIR dyes have a structure according to the general structure At least one of R1/R2, R2/R3, R3/R4, R5/R6, R6/R7, and/or R7/R8 together forms a substituted or unsubstituted cycloalkyl or aryl.

Abstract: Certain embodiments of the present invention are configured to permit development and validation of a device driver or a device application program by using improved virtual devices. Such improved virtual devices facilitate driver development without use of real devices or hardware prototypes. The present invention also may be configured to permit advanced validation of a device-driver combination that would be difficult to achieve even with a real device. Certain embodiments also may detect inconsistencies between virtual and real devices, which may be used to improve drivers and device application programs and increase compatibility of such drivers and device application programs with real devices.

Abstract: The disclosure provides modified chloroquine compounds having single ring or fused ring moieties. Also provided are pharmaceutical compositions comprising such compounds, methods of using such compounds to inhibit or treat diseases or conditions caused by chloroquine-resistant (CQR) and chloroquine-sensitive (CqS) malaria parasites and other CQ-susceptible microorganisms, and processes and intermediates useful for preparing such compounds.

Abstract: Disclosed is a method for nanostructure synthesis that includes growing nanostructures on a layered structure compound at a low temperature using a solution containing a solvent and at least one precursor. The method can include synthesizing and assembling nanowires in essentially the same method step. Disclosed nanostructures and nanowires are substantially uniform in diameter and single crystal. Nanowires can intersect to form networks and can be covalently bonded at points of intersection. Disclosed nanowire networks can be substantially uniform and can form an ordered network. Nanowire networks can be used to fabricate electronic and optical devices.

Abstract: Methods and apparatus for determining a cardiac parameter from cardiovascular pressure signals including arterial blood pressure (ABP) and the photoplethysmographic signal to quantify the degree of amplitude modulation due to respiration and predict fluid responsiveness are disclosed. Disclosed embodiments include a method for assessing fluid responsiveness implemented in a digital computer with one or more processors comprising: (a) measuring a cardiovascular signal, and (b) computing a dynamic index predictive of fluid responsiveness from said cardiovascular signal using a nonlinear state space estimator. According to one particular embodiment, and without limitation, the nonlinear state space estimator is based on a model for cardiovascular signals such as arterial blood pressure or plethysmogram signals, and employs a marginalized particle filter to estimate a dynamic index predictive of fluid responsiveness that is substantially equivalent to a variation in pulse pressure of said cardiovascular signal.

Abstract: This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQR and CQS malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQR reversal moiety. Exemplary RCQ chemical structures are provided. Also provided are pharmaceutical compositions including the disclosed RCQ compounds, and methods of using such compounds and compositions for the treatment of malaria and inhibition of CQR or CQS Plasmodium sp. (such as P. falciparum).

Abstract: Sensors include nano-porous alumina membranes that are sensitized by immobilization of antibodies in the nano-pores. The nano-membranes can be sensitized to respond to a single target compound, or different portions of the nano-membrane can be differently sensitized. Capture of the target compound can be detected based on a spectral signature associated with electrical conductance in the nano-pores.

Abstract: Methods and systems for analyzing samples, such as gas samples, are described. One method comprises providing a gas sample, increasing pressure applied to the gas sample to compress the sample to a smaller volume and provide a pneumatically focused gas sample, and analyzing the pneumatically focused gas sample using any of a variety of analytical techniques. Also disclosed are systems for gas analysis, including systems for analysis of pneumatically focused, and thereby concentrated, gas samples and for analysis of particulate matter in gas samples. Analytical systems constructed within personal computer cases also are disclosed.

Abstract: A method for identifying the redox activity of a subject compound is disclosed. The method can be performed aerobically and can include forming a mixture comprising a free-radical precursor and a compound to be tested, and converting the free-radical precursor into a free-radical anion and a free-radical cation. After the free radical cation and the free radical anion have been formed, the relative redox activity of the subject compound may cause a difference in the rate of photo-bleaching of the mixture and/or the rate of superoxide generation. These differences can be quantified and used to identify the redox activity of the subject compound. This sensitive technique for measuring redox activity can be used to screen compounds for various biological applications. Drugs also can be developed based on the relationship between redox activity and biological activity for particular biological applications.

Abstract: Scanning probe microscope (SPM) images are enhanced by enforcing one or more symmetries that can be selected based on suitable Fourier coefficient amplitude or phase angle residuals, and/or geometric Akaike information criteria, and/or cross correlation techniques. Alternatively, this selection can be based on prior knowledge of specimen characteristics. In addition, a scanning microscope point spread function is obtained based on the evaluation of a calibration image by enforcing at least one symmetry and can be applied to other image acquisitions.

Abstract: Candidate structures for nanocrystal and other specimens are obtained based on a specimen complex spectrum that is determined as a Fourier transform of a phase-contrast electron micrograph. The specimen can also be assessed based on an amplitude portion of the complex spectrum using a lattice-fringe fingerprint. In some examples, the specimen complex spectrum is compensated based on an electron microscope transfer function, a specimen tilt, or based on other crystallographic compensation. Amplitude or phase portions of the compensated complex spectrum can be compared with reference structures stored in one or more reference structure databases.